课题基金 / 基金详情

CORE--CLINICAL LABORATORY FACILITY

CORE--CLINICAL LABORATORY FACILITY
核心--临床实验室设施
批准号:
6315260
负责人:
LEONARD F LIEBES
金额:
$13.42万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-05-19 至 2002-11-30

项目摘要

项目成果

LEONARD F LIEBES的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The overall objective of the Core Clinical Laboratory (CCL) are to provide resources, skilled laboratory technology, and specialized laboratory parameters that are appropriate to monitor and assess the activity of new cytotoxic and immune modulating anti-neoplastic agents. The unit provides a variety of reliable assay methodologies with a high level of quality control, and then supplies the analyzed data to the study investigator. The CCL provides the laboratory support for clinical trials of cytotoxic modalities and trials have pharmacodynamic endpoints. In addition, the CCL supports trials the require assessment of multiple parameters ranging from specialized tests for patient eligibility to quality control of specialized therapeutic modalities. This multiple function evolved from cancer center initiated studies with combination immune- modulating and cytotoxic therapies. The CCL has broadened its function, now providing the appropriate laboratory specialized clinical correlates for the monitoring of these novel approaches to cancer treatment. The primary users of the shared resource are Cancer Center members who need support for their peer reviewed research projects which involved the specialized assays available in the CCL.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Core Clinical Lab
CORE--CLINICAL LABORATORY FACILITY
PHASE I SINGLE DOSE TRIAL OF PEITC (PHENETHYL ISOTHIOCYANATE)
PHASE I SINGLE DOSE TRIAL OF PEITC (PHENETHYL ISOTHIOCYANATE)
海外基金